Literature DB >> 8097922

A population based case-cohort study of drug-induced anaphylaxis.

M M van der Klauw1, B H Stricker, R M Herings, W S Cost, H A Valkenburg, J H Wilson.   

Abstract

1. In order to determine the risk of anaphylaxis as an adverse reaction to drugs, a case-cohort study was performed. Cases consisted of all admissions in 1987 and 1988 to all Dutch hospitals with anaphylaxis as the principal diagnosis, and a random sample of admissions with related symptoms. Hospital discharge summaries were classified according to probability to anaphylaxis by a blinded Audit Committee. Of admissions classified as probable or possible anaphylaxis, the causative agent was assessed. The reference cohort consisted of all persons in the catchment area of a sample of pharmacies in The Netherlands, in the period between January 1, 1987 and December 31, 1988. 2. Out of 934 admissions, discharge summaries on 811 admissions were received, of which 727 contained enough clinical details. Out of 727, 391 were classified as probable or possible anaphylaxis. In 336 of these 391, anaphylaxis was reason for admission. This group consisted of 158 men and 178 women. Drug-induced anaphylaxis occurred in 107 patients. 3. Drug-induced anaphylaxis was most frequently caused by penicillins, analgesics and non-steroidal antiinflammatory drugs (NSAID) with the highest point estimate of the risk relative to all other drugs of 10.7, 6.9 and 3.7 respectively. 4. In the cases of probable anaphylaxis, the risk of anaphylaxis to glafenine relative to all other drugs was 167.7 in 1987 (95%-CI: 63.0-446.4) and 128.6 in 1988 (95%-CI: 50.4-328.5), to amoxycillin 15.2 in 1987 (95%-CI: 5.0-46.0) and 4.4 in 1988 (95%-CI: 1.03-18.9) and to diclofenac 6.1 in 1988 (95%-CI: 1.4-26.1).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097922      PMCID: PMC1381551          DOI: 10.1111/j.1365-2125.1993.tb04157.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  [Anaphylaxis after the use of glafenine].

Authors:  R H Meyboom
Journal:  Ned Tijdschr Geneeskd       Date:  1976-05-22

Review 2.  Anaphylaxis.

Authors:  B S Bochner; L M Lichtenstein
Journal:  N Engl J Med       Date:  1991-06-20       Impact factor: 91.245

3.  [States of shock induced by glafenine and its derivatives].

Authors:  C Sentilhes
Journal:  Rev Odontostomatol (Paris)       Date:  1978 May-Jun

4.  [Anaphylactic accidents due to glaphenine. 5 cases].

Authors:  C Barral; M Faivre
Journal:  Nouv Presse Med       Date:  1975-11-15

5.  [Anaphylactic shock induced by glafenine].

Authors:  A Grand; P Despret
Journal:  Nouv Presse Med       Date:  1973-04

6.  [Acute tubulo-interstitial nephropathy caused by glafenine poisoning].

Authors:  M Gaultier; C Bismuth; M L Efthymiou; L Morel-Maroger; A Romion
Journal:  Nouv Presse Med       Date:  1972-12-23

7.  [Hemodynamic aspects of anaphylactic shock. Apropos of case due to glaphenine].

Authors:  P Sauder; J Kopferschmitt; J F Sagez; A Benmatti; A Jaeger; J M Mantz
Journal:  Rev Med Interne       Date:  1982       Impact factor: 0.728

8.  Design options in epidemiologic research. An update.

Authors:  O Miettinen
Journal:  Scand J Work Environ Health       Date:  1982       Impact factor: 5.024

Review 9.  [Shock caused by glafenine. Apropos of 7 complications].

Authors:  A Davido; P Hallali; T Boutchnei
Journal:  Rev Med Interne       Date:  1989 Mar-Apr       Impact factor: 0.728

10.  Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts.

Authors:  R M Herings; A Bakker; B H Stricker; G Nap
Journal:  J Epidemiol Community Health       Date:  1992-04       Impact factor: 3.710

View more
  22 in total

1.  Attitudinal survey of voluntary reporting of adverse drug reactions.

Authors:  I A Eland; K J Belton; A C van Grootheest; A P Meiners; M D Rawlins; B H Stricker
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

Review 2.  Case-population studies in pharmacoepidemiology.

Authors:  Dolors Capellà; Consuelo Pedrós; Xavier Vidal; Joan-Ramon Laporte
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

Review 3.  Hypersensitivity to pyrazolones.

Authors:  M Levy
Journal:  Thorax       Date:  2000-10       Impact factor: 9.139

4.  Drug Hypersensitivity Reactions Documented in Electronic Health Records within a Large Health System.

Authors:  Adrian Wong; Diane L Seger; Kenneth H Lai; Foster R Goss; Kimberly G Blumenthal; Li Zhou
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-01

5.  Drug-induced anaphylaxis : case/non-case study based on an italian pharmacovigilance database.

Authors:  Roberto Leone; Anita Conforti; Mauro Venegoni; Domenico Motola; Ugo Moretti; Ilaria Meneghelli; Alfredo Cocci; Giulia Sangiorgi Cellini; Stefania Scotto; Nicola Montanaro; Giampaolo Velo
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

6.  In vivo imaging of zebrafish digestive organ function using multiple quenched fluorescent reporters.

Authors:  Kotaro Hama; Elayne Provost; Timothy C Baranowski; Amy L Rubinstein; Jennifer L Anderson; Steven D Leach; Steven A Farber
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-12-04       Impact factor: 4.052

7.  Non-steroidal anti-inflammatory drugs in elderly people. Gastrointestinal bleeding is common.

Authors:  J R Laporte; X Vidal; X Carne
Journal:  BMJ       Date:  1995-08-05

8.  The case-population study design: an analysis of its application in pharmacovigilance.

Authors:  Hélène Théophile; Joan-Ramon Laporte; Nicholas Moore; Karin-Latry Martin; Bernard Bégaud
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

9.  Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.

Authors:  Hélène Théophile; Nicholas Moore; Philip Robinson; Bernard Bégaud; Antoine Pariente
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

Review 10.  Immediate-type hypersensitivity drug reactions.

Authors:  Shelley F Stone; Elizabeth J Phillips; Michael D Wiese; Robert J Heddle; Simon G A Brown
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.